Literature DB >> 2128499

Monoamine oxidase and oxidative stress at dopaminergic synapses.

G Cohen1.   

Abstract

Increased oxidation of dopamine by monoamine oxidase (MAO) in the striatum is associated with an oxidant stress, expressed as a rise in the level of oxidized glutathione. Oxidation of glutathione is suppressed by MAO inhibitors, such as deprenyl and clorgyline. These observations related to Parkinson's disease and to the clinical trial of deprenyl as an agent that may retard progression of the disease.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2128499     DOI： 10.1007/978-3-7091-9113-2_33

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN： 0303-6995


  15 in total

1.  The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).

Authors:  Zhi Dong Zhou; Shao Ping Xie; Wuan Ting Saw; Patrick Ghim Hoe Ho; Hongyan Wang; Zhou Lei; Zhao Yi; Eng King Tan
Journal:  Cells       Date:  2019-08-16       Impact factor: 6.600

Review 2.  Perspectives on MAO-B in aging and neurological disease: where do we go from here?

Authors:  M Jyothi Kumar; Julie K Andersen
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

3.  Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity.

Authors:  J F Marshall; S J O'Dell; F B Weihmuller
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 4.  Monoamine oxidase: from genes to behavior.

Authors:  J C Shih; K Chen; M J Ridd
Journal:  Annu Rev Neurosci       Date:  1999       Impact factor: 12.449

5.  Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium.

Authors:  Y Liu; A Roghani; R H Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

6.  Effects of ageing on the content in sulfur-containing amino acids in rat brain.

Authors:  M S Benedetti; A Russo; P Marrari; P Dostert
Journal:  J Neural Transm Gen Sect       Date:  1991

7.  Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors.

Authors:  Verónica Sandoval; Evan L Riddle; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurosci       Date:  2002-10-01       Impact factor: 6.167

Review 8.  Clinical pharmacokinetics of drugs for Alzheimer's disease.

Authors:  L Parnetti
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

9.  Extensive sequence divergence between the human and rat brain vesicular monoamine transporter: possible molecular basis for species differences in the susceptibility to MPP+.

Authors:  K P Lesch; J Gross; B L Wolozin; D L Murphy; P Riederer
Journal:  J Neural Transm Gen Sect       Date:  1993

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.